Robert Nistico

List of Publications by Year
in descending order

141	5,157	76326	114465
papers	citations	40 h-index	63 g-index

142	142	142	7730
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Î²-Secretase BACE1 in Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 745-756.	1.3	336
2	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Frontiers in Immunology, 2020, 11, 456.	4.8	201
3	A Role for Ca2+ Stores in Kainate Receptor-Dependent Synaptic Facilitation and LTP at Mossy Fiber Synapses in the Hippocampus. Neuron, 2003, 39, 327-341.	8.1	168
4	Inflammation Subverts Hippocampal Synaptic Plasticity in Experimental Multiple Sclerosis. PLoS ONE, 2013, 8, e54666.	2.5	123
5	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 2018, 64, S47-S105.	2.6	122
6	Stress dynamically regulates behavior and glutamatergic gene expression in hippocampus by opening a window of epigenetic plasticity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14960-14965.	7.1	121
7	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449.	4.4	105
8	l-DOPA: A scapegoat for accelerated neurodegeneration in Parkinson's disease?. Progress in Neurobiology, 2011, 94, 389-407.	5.7	100
9	Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology, 2004, 47, 46-64.	4.1	92
10	Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. Scientific Reports, 2016, 5, 17799.	3.3	91
11	Targeting Synaptic Dysfunction in Alzheimerâ€™s Disease Therapy. Molecular Neurobiology, 2012, 46, 572-587.	4.0	80
12	Increased levels of d-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. Molecular and Cellular Neurosciences, 2008, 37, 236-246.	2.2	79
13	Control of PKA stability and signalling by the RING ligase praja2. Nature Cell Biology, 2011, 13, 412-422.	10.3	77
14	New insights on the role of free d-aspartate in the mammalian brain. Amino Acids, 2012, 43, 1861-1871.	2.7	76
15	Na⁺â€“Ca²⁺Exchanger (NCX3) Knock-Out Mice Display an Impairment in Hippocampal Long-Term Potentiation and Spatial Learning and Memory. Journal of Neuroscience, 2011, 31, 7312-7321.	3.6	75
16	Omics sciences for systems biology in Alzheimerâ€™s disease: State-of-the-art of the evidence. Ageing Research Reviews, 2021, 69, 101346.	10.9	74
17	Changes in mGlu5 Receptor-Dependent Synaptic Plasticity and Coupling to Homer Proteins in the Hippocampus of Ube3A Hemizygous Mice Modeling Angelman Syndrome. Journal of Neuroscience, 2014, 34, 4558-4566.	3.6	73
18	Increased d-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiology of Aging, 2011, 32, 2229-2243.	3.1	70

#	Article	IF	Citations
19	Synaptic Plasticity and PDGF Signaling Defects Underlie Clinical Progression in Multiple Sclerosis. Journal of Neuroscience, 2013, 33, 19112-19119.	3.6	70
20	The role of oxidative stress in paraquat-induced neurotoxicity in rats: protection by non peptidyl superoxide dismutase mimetic. Neuroscience Letters, 2003, 335, 163-166.	2.1	69
21	Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. Neurobiology of Disease, 2014, 65, 124-132.	4.4	69
22	Role of Aberrant Striatal Dopamine D₁Receptor/cAMP/Protein Kinase A/DARPP32 Signaling in the Paradoxical Calming Effect of Amphetamine. Journal of Neuroscience, 2010, 30, 11043-11056.	3.6	66
23	Targeting Synaptic Plasticity in Experimental Models of Alzheimerâ€™s Disease. Frontiers in Pharmacology, 2019, 10, 778.	3.5	66
24	Interleukin-1Î² Promotes Long-Term Potentiation in Patients with Multiple Sclerosis. NeuroMolecular Medicine, 2014, 16, 38-51.	3.4	64
25	Advances in the therapy of Alzheimerâ€™s disease: targeting amyloid beta and tau and perspectives for the future. Expert Review of Neurotherapeutics, 2015, 15, 83-105.	2.8	64
26	Persistent increase of d-aspartate in d-aspartate oxidase mutant mice induces a precocious hippocampal age-dependent synaptic plasticity and spatial memory decay. Neurobiology of Aging, 2011, 32, 2061-2074.	3.1	60
27	Therapeutic potential of targeting hydrogen peroxide metabolism in the treatment of brain ischaemia. British Journal of Pharmacology, 2012, 166, 1211-1224.	5.4	58
28	Insulin Receptor Î²-Subunit Haploinsufficiency Impairs Hippocampal Late-Phase LTP and Recognition Memory. NeuroMolecular Medicine, 2012, 14, 262-269.	3.4	58
29	NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease. Aging Cell, 2016, 15, 661-672.	6.7	57
30	The Involvement of Post-Translational Modifications in Alzheimer's Disease. Current Alzheimer Research, 2018, 15, 313-335.	1.4	57
31	Cognitive Impairment and Dentate Gyrus Synaptic Dysfunction in Experimental Parkinsonism. Biological Psychiatry, 2014, 75, 701-710.	1.3	56
32	SUMO: a (Oxidative) Stressed Protein. NeuroMolecular Medicine, 2013, 15, 707-719.	3.4	55
33	The Î³-Secretase Modulator CHF5074 Restores Memory and Hippocampal Synaptic Plasticity in Plaque-Free Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 24, 799-816.	2.6	53
34	Synthesis and Pharmacology of Willardiine Derivatives Acting as Antagonists of Kainate Receptors. Journal of Medicinal Chemistry, 2005, 48, 7867-7881.	6.4	51
35	Exercise interventions in Alzheimerâ€™s disease: A systematic review and meta-analysis of randomized controlled trials. Ageing Research Reviews, 2021, 72, 101479.	10.9	48
36	Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammals. Translational Psychiatry, 2014, 4, e417-e417.	4.8	47

#	Article	IF	Citations
37	RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1405-1412.	3.0	46
38	Precision medicine and drug development in Alzheimerâ€™s disease: the importance of sexual dimorphism and patient stratification. Frontiers in Neuroendocrinology, 2018, 50, 31-51.	5.2	46
39	Calcineurin Inhibition Rescues Early Synaptic Plasticity Deficits in a Mouse Model of Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2013, 15, 541-548.	3.4	45
40	ACET is a highly potent and specific kainate receptor antagonist: Characterisation and effects on hippocampal mossy fibre function. Neuropharmacology, 2009, 56, 121-130.	4.1	44
41	Lithium as a Treatment for Alzheimerâ€™s Disease: The Systems Pharmacology Perspective. Journal of Alzheimer's Disease, 2019, 69, 615-629.	2.6	44
42	Synaptic plasticity in multiple sclerosis and in experimental autoimmune encephalomyelitis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130162.	4.0	43
43	Age-related changes of protein SUMOylation balance in the AÃŽÂ²PP Tg2576 mouse model of Alzheimer's disease. Frontiers in Pharmacology, 2014, 5, 63.	3.5	42
44	d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain. Neurobiology of Aging, 2015, 36, 1890-1902.	3.1	42
45	Presynaptic c-Jun N-terminal Kinase 2 regulates NMDA receptor-dependent glutamate release. Scientific Reports, 2015, 5, 9035.	3.3	41
46	Bv8/prokineticin 2 is involved in AÎ²-induced neurotoxicity. Scientific Reports, 2015, 5, 15301.	3.3	40
47	Aducanumab for Alzheimerâ€™s disease: A regulatory perspective. Pharmacological Research, 2021, 171, 105754.	7.1	40
48	Exploitation of the HIV-1 coat glycoprotein, gp120, in neurodegenerative studies in vivo. Journal of Neurochemistry, 2008, 79, 1-8.	3.9	39
49	Ethanol enhances GABA_Bâ€mediated inhibitory postsynaptic transmission on rat midbrain dopaminergic neurons by facilitating GIRK currents. European Journal of Neuroscience, 2009, 29, 1369-1377.	2.6	39
50	Rhes influences striatal cAMP/PKA-dependent signaling and synaptic plasticity in a gender-sensitive fashion. Scientific Reports, 2015, 5, 10933.	3.3	38
51	The Protective Effect of Superoxide Dismutase Mimetic M40401 on Balloon Injury-Related Neointima Formation: Role of the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 44-50.	2.5	37
52	Kainate Receptors and Mossy Fiber LTP. NeuroToxicology, 2005, 26, 769-777.	3.0	36
53	Synaptoimmunology - roles in health and disease. Molecular Brain, 2017, 10, 26.	2.6	36
54	Targeting Microglia-Synapse Interactions in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2342.	4.1	36

#	Article	IF	Citations
55	HIV-1 Coat Glycoprotein gp120 Induces Apoptosis in Rat Brain Neocortex by Deranging the Arachidonate Cascade in Favor of Prostanoids. Journal of Neurochemistry, 2001, 75, 196-203.	3.9	35
56	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2017, 59, 1327-1334.	2.6	35
57	Neuroprotective effect of hydrogen peroxide on an in vitro model of brain ischaemia. British Journal of Pharmacology, 2008, 153, 1022-1029.	5.4	34
58	Connexin 26 (GJB2) mutations, causing KID Syndrome, are associated with cell death due to calcium gating deregulation. Biochemical and Biophysical Research Communications, 2010, 394, 909-914.	2.1	33
59	Chapter 25 Oxidative Stress in Stroke Pathophysiology. International Review of Neurobiology, 2009, 85, 363-374.	2.0	31
60	Genders and the concurrent use of cocaine and alcohol: Pharmacological aspects. Pharmacological Research, 2014, 87, 60-70.	7.1	31
61	Abnormal Expression of Neuronal Nitric Oxide Synthase Triggers Limbic Seizures and Hippocampal Damage in Rat. Biochemical and Biophysical Research Communications, 2002, 291, 255-260.	2.1	30
62	The effect of inflammatory stimuli on NMDA-related activation of glutamine synthase in human cultured astroglial cells. Neuroscience Letters, 2005, 373, 184-188.	2.1	30
63	D-Aspartate: An Atypical Amino Acid with Neuromodulatory Activity in Mammals. Reviews in the Neurosciences, 2009, 20, 429-40.	2.9	30
64	Physical Exercise and Alzheimerâ€™s Disease: Effects on Pathophysiological Molecular Pathways of the Disease. International Journal of Molecular Sciences, 2021, 22, 2897.	4.1	30
65	The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages. Journal of Leukocyte Biology, 2002, 71, 65-72.	3.3	30
66	Defining and assessing intrinsic capacity in older people: A systematic review and a proposed scoring system. Ageing Research Reviews, 2022, 79, 101640.	10.9	30
67	Evidence that increases of mitochondrial immunoreactive IL-1Î² by HIV-1 gp120 implicatein situcleavage of pro-IL-1Î² in the neocortex of rat. Journal of Neurochemistry, 2001, 78, 611-618.	3.9	29
68	The Blockade of K+â€ATP Channels has Neuroprotective Effects in an In Vitro Model of Brain Ischemia. International Review of Neurobiology, 2007, 82, 383-395.	2.0	29
69	Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice. Experimental Neurology, 2014, 261, 733-743.	4.1	29
70	Feedback inhibition of cAMP effector signaling by a chaperone-assisted ubiquitin system. Nature Communications, 2019, 10, 2572.	12.8	29
71	Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug Design, Development and Therapy, 2013, 7, 1359.	4.3	28
72	Paradoxical Abatement of Striatal Dopaminergic Transmission by Cocaine and Methylphenidate. Journal of Biological Chemistry, 2014, 289, 264-274.	3.4	27

#	Article	IF	Citations
73	Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions. Neuropharmacology, 2014, 76, 127-136.	4.1	27
74	Selective regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G protein-coupled receptor kinases and arrestins. Neuropharmacology, 2014, 77, 303-312.	4.1	27
75	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology, 2021, 185, 108081.	4.1	27
76	Learning discloses abnormal structural and functional plasticity at hippocampal synapses in the APP23 mouse model of Alzheimer's disease. Learning and Memory, 2010, 17, 236-240.	1.3	26
77	Targeting SUMO-1ylation Contrasts Synaptic Dysfunction in a Mouse Model of Alzheimerâ€™s Disease. Molecular Neurobiology, 2017, 54, 6609-6623.	4.0	26
78	Synaptic plasticity in the basal ganglia: A similar code for physiological and pathological conditions. Progress in Neurobiology, 2008, 84, 343-362.	5.7	25
79	Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia. Pharmacological Research, 2014, 81, 83-90.	7.1	22
80	Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an inÂvitro model of Alzheimer's disease. Neuropharmacology, 2017, 116, 82-97.	4.1	21
81	Neuregulin 1/ErbB signalling modulates hippocampal mGluRI-dependent LTD and object recognition memory. Pharmacological Research, 2018, 130, 12-24.	7.1	21
82	Apoptosis in the Dorsal Lateral Geniculate Nucleus after Monocular Deprivation Involves Glutamate Signaling, NO Production, and PARP Activation. Biochemical and Biophysical Research Communications, 2000, 278, 360-367.	2.1	19
83	Enhanced mGlu5-receptor dependent long-term depression at the Schaffer collateral-CA1 synapse of congenitally learned helpless rats. Neuropharmacology, 2013, 66, 339-347.	4.1	19
84	Ginkgolic Acid Protects against AÎ²-Induced Synaptic Dysfunction in the Hippocampus. Frontiers in Pharmacology, 2016, 7, 401.	3.5	19
85	The role of adiponectin receptors in the regulation of synaptic transmission in the hippocampus. Synapse, 2017, 71, e21964.	1.2	19
86	Early alteration of distribution and activity of hippocampal type-1 cannabinoid receptor in Alzheimerâ€™s disease-like mice overexpressing the human mutant amyloid precursor protein. Pharmacological Research, 2018, 130, 366-373.	7.1	19
87	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140537.	2.3	19
88	Growth Factors and Synaptic Plasticity in Relapsingâ€“Remitting Multiple Sclerosis. NeuroMolecular Medicine, 2014, 16, 490-498.	3.4	18
89	5-HT2C serotonin receptor blockade prevents tau protein hyperphosphorylation and corrects the defect in hippocampal synaptic plasticity caused by a combination of environmental stressors in mice. Pharmacological Research, 2015, 99, 258-268.	7.1	18
90	Acid-sensing ion channel 1a is required for mGlu receptor dependent long-term depression in the hippocampus. Pharmacological Research, 2017, 119, 12-19.	7.1	18

#	Article	IF	Citations
91	Synergistic interactions between kainate and mGlu receptors regulate bouton Ca2+ signalling and mossy fibre LTP. Scientific Reports, 2011, 1, 103.	3.3	17
92	Bromelain Degrades AÎ²1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients. Current Alzheimer Research, 2018, 15, 628-636.	1.4	17
93	The protective effect of M40401, a superoxide dismutase mimetic, on post-ischemic brain damage in Mongolian gerbils. BMC Pharmacology, 2003, 3, 8.	0.4	16
94	Huperzine A Restores Cortico-Hippocampal Functional Connectivity after Bilateral AMPA Lesion of the Nucleus Basalis of Meynert. Journal of Alzheimer's Disease, 2013, 35, 833-846.	2.6	16
95	Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapy. Frontiers in Pharmacology, 2015, 6, 122.	3.5	16
96	Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone. Pharmacological Research, 2016, 108, 31-38.	7.1	16
97	Recovery of hippocampal functions and modulation of muscarinic response by electroacupuncture in young diabetic rats. Scientific Reports, 2017, 7, 9077.	3.3	16
98	Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation. Neuroscience, 2013, 252, 118-124.	2.3	15
99	Unlocking the secrets of dopamine in Alzheimerâ€™s Disease. Pharmacological Research, 2018, 128, 399.	7.1	15
100	A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects. Current Neuropharmacology, 2021, 19, 610-628.	2.9	15
101	Differential effect of carbamazepine and oxcarbazepine on excitatory synaptic transmission in rat hippocampus. Synapse, 2008, 62, 783-789.	1.2	14
102	Subtle alterations of excitatory transmission are linked to presynaptic changes in the hippocampus of PINK1â€deficient mice. Synapse, 2016, 70, 223-230.	1.2	14
103	Neurodegenerative Disease: What Potential Therapeutic Role of Acid-Sensing Ion Channels?. Frontiers in Cellular Neuroscience, 2021, 15, 730641.	3.7	12
104	Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740. Neuropharmacology, 2014, 86, 133-144.	4.1	11
105	Synaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders. Current Pharmaceutical Design, 2013, 19, 6480-6490.	1.9	11
106	Age-Related Changes of Hippocampal Synaptic Plasticity in AÎ²PP-Null Mice are Restored by NGF Through p75NTR. Journal of Alzheimer's Disease, 2012, 33, 265-272.	2.6	11
107	Unbalance between Excitation and Inhibition in Phenylketonuria, a Genetic Metabolic Disease Associated with Autism. International Journal of Molecular Sciences, 2017, 18, 941.	4.1	10
108	Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria. Frontiers in Neuroscience, 2018, 12, 154.	2.8	10

#	Article	IF	Citations
109	The selective disruption of presynaptic JNK2/STX1a interaction reduces NMDA receptor-dependent glutamate release. Scientific Reports, 2019, 9, 7146.	3.3	10
110	Central cardiovascular responses induced by interleukin 1Î² and tumor necrosis factor Î± infused into nucleus tractus solitarii, nucleus parabrachialis medialis and third cerebral ventricle of normotensive rats. Neuroscience Letters, 2001, 314, 53-56.	2.1	7
111	Inhibition of hippocampal plasticity in rats performing contrafreeloading for water under repeated administrations of pramipexole. Psychopharmacology, 2016, 233, 727-737.	3.1	7
112	Electroacupuncture in rats normalizes the diabetesâ€induced alterations in the septoâ€hippocampal cholinergic system. Hippocampus, 2019, 29, 891-904.	1.9	7
113	Role of ASIC1a in Normal and Pathological Synaptic Plasticity. Reviews of Physiology, Biochemistry and Pharmacology, 2020, 177, 83-100.	1.6	7
114	Chapter 2 Gluk1 Receptor Antagonists and Hippocampal Mossy Fiber Function. International Review of Neurobiology, 2009, 85, 13-27.	2.0	6
115	Characterization of gene expression induced by RTN-1C in human neuroblastoma cells and in mouse brain. Neurobiology of Disease, 2010, 40, 634-644.	4.4	6
116	Involvement of Bradykinin Receptor 2 in Nerve Growth Factor Neuroprotective Activity. Cells, 2020, 9, 2651.	4.1	6
117	The positive allosteric modulator at mGlu2 receptors, LY487379, reverses the effects of chronic stressâ€induced behavioral maladaptation and synaptic dysfunction in the adulthood. Synapse, 2019, 73, e22101.	1.2	5
118	PDGF Modulates Synaptic Excitability and Short-Latency Afferent Inhibition in Multiple Sclerosis. Neurochemical Research, 2019, 44, 726-733.	3.3	5
119	Nonclinical data supporting orphan medicinal product designations in the area of rare infectious diseases. Drug Discovery Today, 2020, 25, 274-291.	6.4	5
120	Excitotoxic Mechanisms of Apoptosis in the Mammalian Visual System Following Monocular Visual Deprivation. Basic and Clinical Pharmacology and Toxicology, 2002, 91, 153-157.	0.0	4
121	SUMOylation in Neuroplasticity and Neurological Disorders. NeuroMolecular Medicine, 2013, 15, 637-638.	3.4	4
122	The changing landscape of treatment options in childhood acute lymphoblastic leukaemia. Drug Discovery Today, 2022, , .	6.4	4
123	Nâ€ethyl lidocaine (QXâ€314) protects striatal neurons against ischemia: An in vitro electrophysiological study. Synapse, 2010, 64, 161-168.	1.2	3
124	Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefitâ€"The EU Regulator's Perspective. Frontiers in Medicine, 2021, 8, 744625.	2.6	3
125	Exploiting Focused Ultrasound to Aid Intranasal Drug Delivery for Brain Therapy. Frontiers in Pharmacology, 2022, 13, 786475.	3.5	3
126	Optimising bench science to withstand regulatory scrutiny. Pharmacological Research, 2019, 139, 491-493.	7.1	2

#	Article	IF	Citations
127	Reply to the article â€œManagement of status epilepticus in adults. Position paper of the Italian League against Epilepsyâ€• Epilepsy and Behavior, 2020, 107, 106866.	1.7	2
128	Dexamethasone Inhibits the Inducible Bioconversion of Glyceryl Trinitrate to Nitric Oxide. Journal of Cardiovascular Pharmacology, 2002, 39, 544-551.	1.9	1
129	Editorial Thematic Issue: Targeting Synaptic Dysfunction and Neural Connectivity in Neurological and Psychiatric Disorders. Current Pharmaceutical Design, 2013, 19, 6391-6392.	1.9	1
130	Effects of intranasally-delivered pro-nerve growth factors on the septo-hippocampal system in healthy and diabetic rats. Neuropharmacology, 2020, 176, 108223.	4.1	1
131	Biological Mechanism-based Neurology and Psychiatry: a BACE1/2 and Downstream Pathway Model. Current Neuropharmacology, 2021, 19, .	2.9	1
132	Potential therapeutic usefulness of hydrogen peroxide in conditions of brain ischemia. Medical Hypotheses, 2008, 71, 162.	1.5	0
133	Single or combined treatment with l-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells. Neuroscience Letters, 2013, 552, 168-173.	2.1	0
134	B.11 - PRAMIPEXOLE DISRUPTS SYNAPTIC PLASTICITY IN THE CA1 AREA OF THE HIPOCAMPUS OF RATS THAT DEVELOP CONTRAFREELOADING FOR WATER, AN ANIMAL MODEL OF COMPULSIVE BEHAVIOR. Behavioural Pharmacology, 2013, 24, e29.	1.7	0
135	NS.4.2 - PRAMIPEXOLE DISRUPTS SYNAPTIC PLASTICITY IN THE CA1 AREA OF THE HIPOCAMPUS OF RATS THAT DEVELOP CONTRAFREELOADING FOR WATER, AN ANIMAL MODEL OF COMPULSIVE BEHAVIOR. Behavioural Pharmacology, 2013, 24, e21.	1.7	0
136	Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]. Drug Design, Development and Therapy, 0, , 569.	4.3	0
137	[P2â€“260]: TWOâ€ŁLEVEL DIAGNOSTIC CLASSIFICATION USING CEREBROSPINAL FLUID NEUROGRANIN IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P712.	0.8	0
138	Alzheimerâ€™s disease: understanding homeostasis deregulation to foster development of effective therapies. Pharmacological Research, 2019, 139, 467-468.	7.1	0
139	Reply to the reply of the authors of the review article entitled â€œManagement of status epilepticus in adults. Position paper of the Italian League against Epilepsyâ€• Epilepsy and Behavior, 2020, 110, 107168.	1.7	0
140	Gutâ€“brain axis: Physiology and pathology. , 2018, , .		0
141	Impairment of hippocampal synaptic plasticity induced by pathological microglial activation. Alzheimer's and Dementia, 2021, 17, .	0.8	0